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H eart failure with preserved ejection fraction (HFpEF) is agrowing public health problem that accounts for
approximately half of all prevalent heart failure (HF).1,2 Once
believed to carry a favorable prognosis compared with HF and
reduced ejection fraction (HFrEF), contemporary data suggest
that both groups face similar outcomes in the community
setting.1,3 Although survival rates for patients with chronic
HFrEF have improved in the last 2 decades with advances in
drug and device-based therapies, there has been no such
parallel progress in HFpEF management,4 and treatment
remains largely limited to the active recognition and treat-
ment of comorbidities and the use of diuretics. The
prevalence of HFpEF relative to HFrEF continues to rise at
1% per year, projecting it to be the more common form of
HF over the next decade.5,6 HFpEF is particularly common in
the elderly and is associated with a signiﬁcant risk of death,
hospitalization and suboptimal quality of life. Thus, there
remains an enormous unmet need for effective therapy for
this group of patients.7,8
Augmentation of cyclic guanosine monophosphate (cGMP)
signaling is recognized as a potential therapeutic strategy in
HFpEF based on several preclinical and clinical studies that
have investigated various mechanisms and effects of cGMP
enhancement.7,9–14 However, the recent neutral result of the
Effect of Phosphodiesterase-5 Inhibition on Exercise Capacity
and Clinical Status in Heart Failure with Preserved Ejection
Fraction (RELAX) trial with the phosphodiesterase-5 (PDE-5)
inhibitor sildenaﬁl has challenged this strategy.11 Neverthe-
less, there are multiple pharmacologic strategies for cGMP
pathway modulation and the effects of an intervention might
vary with the mode and pathway site of action. In this article,
we review the physiology and pathophysiology of the cGMP
signaling pathway as it relates to HFpEF, discuss the various
pharmacologic mechanisms for pathway modulation, appraise
the current body of evidence for the multiple agents targeting
cGMP enhancement, and outline future directions for drug
development targeting cGMP enhancement as treatment for
HFpEF.
The cGMP Signaling Cascade
Guanylate cyclases represent a widely distributed family of
enzymes that convert guanosine triphosphate to the second-
messenger molecule cGMP.15 The 2 primary forms are the
transmembrane-associated particulate guanylate cyclase,
which functions as a receptor for natriuretic peptides, and
the soluble guanylate cyclase (sGC), which serves as a
receptor for nitric oxide (NO) (Figure 1).16 The physiologic
actions of cGMP are mediated through intracellular effector
molecules, namely, cGMP-dependent protein kinases, cGMP-
gated ion channels, and cGMP-regulated phosphodiesteras-
es.17,18 cGMP contributes to the normal function of vital
organs, and alterations in signaling have been implicated in
derangements of multiple end-organ systems.15,19–24
cGMP and HFpEF Pathophysiology
Once thought synonymous with diastolic dysfunction, HFpEF
is now understood as a complex interplay between increased
left ventricular (LV) and peripheral vascular stiffness, right and
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CONTEMPORARY REVIEWS
LV diastolic and systolic dysfunction, and chronotropic
incompetence that results in abnormal ventricular relaxation
and elevated LV end-diastolic pressures.5 This mechanistic
understanding provides compelling rationale for targeting
cGMP activity (Figure 2).25
Diastolic Function
LV diastolic dysfunction is universally seen in HFpEF, and
many patients have evidence of increased LV mass or relative
wall thickness.26 sGC may reduce myoﬁlament calcium
sensitivity and exert beneﬁcial effects on cross-bridge
detachment, consistent with the ability of the NO donor
sodium nitroprusside to increase cGMP generation and
hasten LV relaxation.27 A more recently characterized
mechanism may be activation of cGMP-dependent protein
kinases, which have been shown to favorably inﬂuence
ventricular hypertrophy, and diastolic relaxation and stiff-
ness.13,28–30
Systolic Function
Despite preserved LV ejection fraction, many HFpEF patients
have concurrent systolic dysfunction.31 Regional measures of
systolic function with tissue Doppler may show depression of
both longitudinal and radial ventricular contractile function.32–35
Moreover, there is an elevation in end-systolic elastance and
passive ventricular stiffening.31,36 In the myocardium, sGC
modulates contractility and attenuates adrenergic stimula-
tion.37–43 However, beyond these myocardial effects, reversal
of cardiac endothelial dysfunction may improve ventricular
performance secondary to improvement in coronary blood
ﬂow.44
Structural Cardiac Changes
Many HFpEF patients have increased LV mass or relative wall
thickness and may have concentric remodeling or hypertrophy.
Total LV chamber size is typically normal or near normal, but the
Figure 1. cGMP signaling pathways. cGMP is the second messenger of 2 distinct signaling pathways: (1) NO is produced by endothelial cells
and binds to sGC in the target cell; and (2) ANP and BNP, derived primarily from cardiomyocytes, stimulate GC-A, whereas CNP, secreted by
endothelial cells, stimulates GC-B. cGMP signaling may be augmented by (1) the use of NO mimetics such as nitrovasodilators; (2) sGC activators
or stimulators; (3) increasing levels of natriuretic peptides; (4) by inhibiting natriuretic peptide degrading enzymes; and (5) inhibiting the activity of
cGMP-hydrolyzing PDEs. ANP indicates atrial natriuretic peptide; BNP, B-type natriuretic peptide; cGMP, cyclic guanosine monophosphate; CNP,
C-type natriuretic peptide; DPP4, dipeptidyl peptidase IV; GC, guanylate cyclase; GMP, guanosine monophosphate; NEP, neutral endopeptidase;
NO, nitric oxide; PDE, phosphodiesterase; PKG, protein kinase G; RA, natriuretic peptide receptor A; sGC, soluble guanylate cyclase. Adapted with
permission from Boerrigter et al.16
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cardiomyocytes themselves may have increased diameter
compared with HFrEF.45 Likewise, changes in the interstitial
matrix, notably ﬁbrosis, have been described. Experimental
models of cardiac ﬁbroblast activation have inducedHF through
generation of diffuse ﬁbrosis,46 which in turn is associated with
diastolic dysfunction47 and risk of arrhythmia or death.48–50
Agents targeting cGMP signaling elicit antihypertrophic effects
and may favorably inﬂuence cardiac remodeling at doses not
affecting blood pressure51 and attenuate cardiac ﬁbrosis.52,53
cGMP-Dependent Protein Kinase Phosphorylation
Novel molecular understanding of cardiac mechanotransduc-
tion in normal and failing myocardium has provided an added
perspective on the role of cGMP and protein kinase G (PKG) in
HFpEF. Titin, a protein anchored to the sarcomere Z-line that
serves as a major determinant of myocardial passive tension
and stiffness, can be modulated via phosphorylation.54,55
Although the ability of cAMP-dependent protein kinase A to
phosphorylate titin had been well known, it was more recently
discovered that PKG can mediate similar phosphorylation in
both dog and human hearts.29,56 This posttranslational
modiﬁcation promotes reduction in titin-based passive ten-
sion and thus may represent a promising therapeutic target
for reducing myocardial stiffness. A study of myocardial
biopsies among patients with HFpEF, HFrEF, and aortic
stenosis evaluated the relationship between cardiac PKG,
cardiomyocyte resting tension, and upstream regulation with
levels of cGMP, natriuretic peptides, and oxidative stress.13 Of
the 3 cohorts, HFpEF had signiﬁcantly lower PKG and cGMP
activity, high myocardial resting tension, and a higher degree
of oxidative stress (Figure 3).13 In vitro administration of PKG
resulted in signiﬁcantly greater improvement in resting
tension among HFpEF patients relative to those with HFrEF
and aortic stenosis.
Vascular Function and Stiffness
Patients with HFpEF have signiﬁcantly impaired systemic
vasorelaxation with exercise, limiting cardiac output
reserve under stress,57–59 and exhibit limited ﬂow-mediated
Figure 2. cGMP signaling and myocardial dysfunction and remod-
eling in HFpEF. Comorbidities induce a systemic proinﬂammatory
state with elevated plasma levels of interleukin (IL)–6, tumor necrosis
factor (TNF)–a, soluble ST2 (sST2), and pentraxin 3. Coronary
microvascular endothelial cells reactively produce reactive oxygen
species (ROS), vascular cell adhesion molecules (VCAMs), and
E-selectin. Production of ROS leads to formation of peroxynitrite
(ONOO) and reduced nitric oxide (NO) bioavailability, both of which
lower soluble guanylate cyclase (sGC) activity in adjacent cardio-
myocytes. Lower sGC activity decreases cyclic guanosine mono-
phosphate concentration and protein kinase G (PKG) activity. Low
PKG activity increases resting tension (Fpassive) of cardiomyocytes
because of hypophosphorylation of titin and removes the brake on
prohypertrophic stimuli inducing cardiomyocyte hypertrophy. VCAM
and E-selectin expression in endothelial cells favors migration into
the subendothelium of monocytes. These monocytes release trans-
forming growth factor b (TGF-b). The latter stimulates conversion of
ﬁbroblasts to myoﬁbroblasts, which deposit collagen in the intersti-
tial space. cGMP indicates cyclic guanosine monophosphate; COPD,
chronic obstructive pulmonary disease; HFpEF, heart failure with
preserved ejection fraction. Adapted and modiﬁed with permission
from Paulus and Tschope.25
Figure 3. PKG activity and cGMP concentration in myocardial
tissue from patients with heart failure with reduced and preserved
ejection fraction and aortic stenosis. AS indicates aortic stenosis;
cGMP, cyclic guanosine monophosphate; HFpEF, heart failure with
preserved ejection fraction; HFrEF, heart failure with reduced
ejection fraction; PKG, protein kinase G. Adapted and modiﬁed with
permission from van Heerebeek et al.13
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vasodilation compared with healthy age-matched controls,58
implicating the role of endothelial dysfunction. Moreover,
endothelial dysfunction corresponds to the severity of HF
symptoms, exercise capacity, and exertional intolerance.58
NO-dependent regulation is a signiﬁcant modulator of vascu-
lar tone, and decreased NO bioavailability in HFpEF favors
vasoconstriction and vascular stiffness, amplifying afterload.
Decreased NO bioavailability may also upregulate sympathetic
drive and catecholamine release,60 and enhance endothelin-
1-induced vasocontriction.61
Pulmonary Hypertension
Among elderly patients with a normal LV ejection fraction,
HFpEF is the most common cause of elevated pulmonary
pressures.62 Elevated pulmonary artery pressure is predictive
of increased mortality in HFpEF.63 High LV end-diastolic
pressures can induce both a passive increase in pulmonary
artery pressure via retrograde pressure transmission, and a
reactive increase in pulmonary vascular resistance with
elevations in the transpulmonary gradient out of proportion
to the LV end-diastolic pressure.64 Enhancement of cGMP in
patients with pulmonary arterial hypertension improves
hemodynamics, functional status, and exercise capacity.65
Given the signiﬁcant overlap between diastolic dysfunction
and pulmonary hypertension, it has been hypothesized that
cGMP modulating agents efﬁcacious in pulmonary arterial
hypertension would be beneﬁcial in HFpEF, but this has yet to
be deﬁnitively proven.11
Renal Function
Preclinical data suggest a role for cGMP in regulation of renal
function with possible mechanisms including hemodynamic-
associated and hemodynamic-independent modulation of
endothelial function and organ ﬁbrosis. Direct stimulation of
sGC in acute and chronic glomerulonephritis may attenuate
renal dysfunction and limit progressive sclerosis and matrix
deposition.23,66,67 Long-term sGC activation prevented
increases in blood pressure, preserved renal function, improved
natriuretic peptide levels, reduced LV hypertrophy, and slowed
progress of renal disease in a rat model of chronic renal
failure.68 In a canine HF model, pharmacologic targeting of
cGMP increased renal blood ﬂow and reducedmean arterial and
pulmonary capillary wedge pressure without concurrent
decreases in glomerular ﬁltration rate or upregulation of the
renin-angiotensin-aldosterone system.69
Other Peripheral Effects
Endothelial dysfunction has also been associated with abnor-
mal ergoreﬂex and metaboreﬂex actions, which lead to
excessive ventilation in HF patients with exercise.70 Guazzi
et al observed that treatment with the PDE-5 inhibitor sildenaﬁl
improved this ergoreﬂex activation and that the magnitude of
improvement correlated with enhancement in ﬂow-mediated
arterial dilatation.70 In addition, recent studies have shown that
many patients with HFpEF display abnormalities in peripheral
oxygen utilization, uptake, or distribution in skeletal muscle that
contribute to functional disability and symptoms.71,72 As NO is
known to play a key role in the regulation of mitochondrial
respiration, perfusion, and excitation-contraction coupling in
skeletal muscle,73 it is plausible that cGMP enhancement would
carry additional beneﬁts for HFpEF patients outside the heart
and vasculature.
Disturbed cGMP Signaling and Strategies for
Enhancement
Recently, a novel paradigm has been proposed that supports
the critical role of deranged cGMP signaling in HFpEF patho-
physiology.25 It is proposed that the various comorbidities
common to HFpEF patients foster a systemic inﬂammatory
state contributing to endothelial dysfunction, reactive oxygen
species production, nitrosative stress, and depressed NO
bioavailability. This decreased NO bioavailability results in poor
cGMP-dependent PKG signaling, with consequent effects on
cardiac hypertrophy, relaxation, and stiffness. Consistent with
this paradigm, multiple preclinical and clinical trials have
explored or are planning to study the role of novel therapeutic
interventions at various levels in the cGMP-signaling pathway.
Nitric Oxide Donors and Nitrates
NO sits at the most upstream location of the cGMP pathway,
and multiple studies have investigated it as a therapeutic
target in HFpEF. Exogenous NO exerts a negative inotropic
effect at high doses with earlier ventricular relaxation74 and
leads to a rightward shift of the length–tension relation-
ship.75,76 Intracoronary infusion of nitroprusside results in a
decrease in LV peak systolic pressure and increases in
diastolic distensibility.77 Aside from effects on inotropy and
ventricular compliance, NO is a mediator of myocardial
energetics through regulation of mitochondrial respiration,
oxygen consumption, and substrate utilization.77 However,
tolerance is a well-recognized limitation of organic nitrates,
and both oxidative stress and impaired bioactivation of NO in
HF may blunt the long-term effects of nitrate therapy.78
Furthermore, chronic treatment with nitrates may cause
oxidative stress via increased expression of endothelin, hence
potentially exacerbating endothelial dysfunction.79 Also,
HFpEF patients were found to be 4 times more likely than
those with HFrEF to experience a reduction in stroke volume
with nitroprusside, suggesting greater vulnerability to preload
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reduction.80 Thus, although NO donors may be helpful in
reducing LV ﬁlling pressures, cGMP enhancement via other
agents with different regional vasoactivity may be preferred to
minimize the risk of tolerability-limiting preload and blood
pressure reduction. The National Institutes of Health plans to
perform a small pilot study with oral nitrates assessing
exercise tolerance in HFpEF patients to further explore the
effect of cGMP modulation via nitrates.
Phosphodiesterase-5 Inhibition
An alternative approach is to inhibit catabolism of cGMP
through PDE-5 inhibition. PDE-5 inhibition blunts adrenergic
stimulation,40 attenuatesmaladaptivemyocardial remodeling,30
improves endothelial function,81 and enhances the renal
response to natriuretic peptides.82 Commonly used for pulmo-
nary arterial hypertension,65 several small studies have
explored the use of sildenaﬁl in HFrEF patients with favorable
results.70,83–85 In HFpEF, a single-center study of 44 patients
found signiﬁcant improvements in central hemodynamics, left
and right ventricular function, and lung function with PDE-5
inhibition.10 However, in the multicenter RELAX trial, which
included 216 stable ambulatory HFpEF patients,11 sildenaﬁl
failed to signiﬁcantly improve peak exercise oxygen consump-
tion, clinical status rank score, or 6-minute walk distance at
24 weeks. In addition, there were no hemodynamic effects,
including changes in systemic vascular resistance, consistent
with a study of the drug in HFrEF and secondary pulmonary
hypertension.84Moreover, therewere no signiﬁcant differences
in plasma cGMP levels between sildenaﬁl and placebo groups.
The investigators postulated that the lack of a positive trial
result may be related to the relativelymodest level of pulmonary
hypertension and LV hypertrophy in the RELAX trial compared
with the study by Guazzi and colleagues, in which right
ventricular function was markedly impaired with baseline right
atrial pressures of 23 mm Hg, mean baseline pulmonary
artery systolic pressure >50 mm Hg, and LV mass index
>160 g/m2.10 An alternative explanation centers on the lack of
signiﬁcant increase in plasma cGMP with sildenaﬁl, suggesting
a failure to adequately test the cGMP enhancement hypothesis.
Along these lines, upregulation of PDE-5 has not been
deﬁnitively shown to be the underlying mechanism of reduced
cGMP signaling in HFpEF, and it may be less important to inhibit
this enzyme if decreased cGMP production is instead the
predominant problem.13,30
sGC Activation and Stimulation
In the last 15 years, 2 classes of compounds have been
discovered that are capable of modulating sGC in a
NO-independent manner, the so-called sGC activators and
sGC stimulators (Figure 4).86
In addition to reducing NO bioavailability, reactive oxygen
species are capable of downstream cGMP pathway modula-
tion via sGC inactivation. A reduced ferrous heme prosthetic
group is required for sGC to facilitate NO-dependent cGMP
stimulation. Oxidative stress shifts intracellular levels of
native sGC toward the oxidized, dysfunctional, heme-free
form that is unresponsive to both endogenous and exogenous
NO.15,87 This concept of NO resistance provides the rationale
for sGC activators that bind to the unoccupied sGC heme-
binding site, thereby favoring the active enzyme state.88 The
pharmacologic efﬁcacy proﬁle of cinaciguat, an intravenous
sGC activator, has been explored in various in vivo models of
myocardial infarction, chronic renal failure, and pulmonary
hypertension. In a canine HF model, cinaciguat resulted in
dose-dependent reductions in preload and afterload and a
concomitant increase in cardiac output and renal blood ﬂow
without further neurohormonal activation.89 To date, pub-
lished studies with sGC activators in human HF have been
restricted to HFrEF. Although these agents demonstrate the
ability to attenuate remodeling at doses that do not affect
blood pressure in rodent models,90 a short-term infusion of
cinaciguat in a phase II program of HFrEF had to be
prematurely terminated partly because of excess hypoten-
sion.91 Future studies are required to test if the vascular and
myocardial beneﬁts seen in animal models with sGC activa-
tors can be reproduced in HFpEF patients.
In comparison to activators, sGC stimulators stimulate the
enzyme by mimicking NO, thus overcoming the relative NO-
deﬁcient state.88 Preclinical models with these agents have
demonstrated reductions in renal and cardiac ﬁbrosis,
decreased LV mass, and anti-inﬂammatory properties.53,92,93
Recently, 2 placebo-controlled phase III trials were published
demonstrating beneﬁcial effects of the sGC stimulator
riociguat on 6-minute walk distance, natriuretic peptide
levels, and functional class in patients with WHO Group 1
and Group 4 pulmonary hypertension.94,95 A phase IIb study in
HFrEF patients testing riociguat failed to show a beneﬁt for
the primary end point of pulmonary artery pressure, but did
show improvements in pulmonary and systemic vascular
resistance, cardiac output, stroke volume, and quality-of-life
scores.96 To test this pathway further in HFpEF, a trial with a
once-daily oral sGC stimulator, BAY1021189, is currently
under way.
Neprilysin Inhibition
Natriuretic peptide levels are a strong predictor of prognosis
in HF, irrespective of LV ejection fraction.97 Natriuretic
peptides stimulate diuresis, natriuresis, and vasodilation and
may have antiﬁbrotic and antiadrenergic effects.98,99 These
physiologic effects are mediated, in part, through 3
natriuretic peptide receptors, 2 of which are transmembrane
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guanylyl cyclases capable of catalyzing cGMP.99 Neprilysin
enzymatically degrades B-type natriuretic peptide (BNP), but
not N-terminal pro-B-type natriuretic peptide (NT-proBNP),
and compounds combining neprilysin inhibition with renin-
angiotensin-aldosterone blockade are actively being tested
in human HF. In HFrEF, omapatrilat, a combined neprilysin
and angiotensin-converting enzyme (ACE) inhibitor, demon-
strated similar effects on outcomes compared with ACE
inhibitors alone, but excess angioedema halted further drug
development.100 Recently, LCZ696, a ﬁrst-in-class angioten-
sin receptor/neprilysin inhibitor, was tested in 301 patients
with HFpEF. Compared with valsartan, the study drug led to
greater reductions in NT-proBNP at 12 weeks and was
safely tolerated.12 LCZ696 also signiﬁcantly increased
urinary cGMP/creatinine ratio at 12 and 36 weeks relative
to valsartan (S.D. Solomon, MD, unpublished data, personal
communication). Whether the observed favorable effect on
NT-proBNP and cGMP will translate into improved clinical
outcomes will be tested in a larger ongoing phase III
program.
Future Directions With cGMP Enhancement
in HFpEF
The body of evidence surrounding cGMP enhancement
provides compelling rationale for further investigation of this
pathway in HFpEF. Although the initial phase III attempt with
PDE-5 inhibition produced a neutral result, the hypothesis of
cGMP upregulation in HFpEF remains to be deﬁnitively tested.
Although animal studies suggest low PKG activity in HFpEF
stems largely from elevated PDE-5 activity,56 the aforemen-
tioned study by van Heerebeek and colleagues does not
support this notion.13 In that study, although myocardial
levels of PKG and cGMP were signiﬁcantly reduced in patients
with HFpEF compared with those with HFrEF and aortic
stenosis, there was no difference in cardiac expression of
PDE-5 between HFpEF patients and the other groups.
Moreover, no differences in myocardial sGC level were
observed, although it is unclear what fraction of the detected
enzyme was optimally active.88 Taken together, these results
suggest that the cGMP and PKG deﬁciency seen in HFpEF
Figure 4. Schematic representation of the mechanism(s) by which NO-independent sGC stimulators and sGC activators ﬁt into the NO/sGC/
cGMP pathway. Oxidative stress—a risk factor for several cardiovascular diseases—is associated with increased formation of reactive oxygen
species that are known to oxidize and inactivate many biomolecules, culminating in tissue damage. In particular, ONOO oxidizes sGC, resulting in
loss of the heme group. Heme-free sGC is unable to respond to NO and can be regarded as a dysfunctional form of the enzyme (NO stimulates
only the native form of sGC). Stimulators of sGC have a dual mode of action: they directly stimulate the native form of the enzyme and make it
more sensitive to endogenous NO. Activators of sGC speciﬁcally activate dysfunctional or heme-free sGC. Stimulation of native sGC and
activation of heme-free sGC both lead to increased formation of cGMP, which exerts a profound, multifaceted cytoprotective effect. cGMP
indicates cyclic guanosine monophosphate; GMP, guanosine monophosphate; GTP, guanosine triphosphate; NO, nitric oxide; NOS, nitric oxide
synthase; ONOO, peroxynitrite; PDE, phosphodiesterase; sGC, soluble guanylate cyclase. Adapted and modiﬁed with permission from Hobbs and
Stasch.86
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manifests from reduced upstream production and bioavail-
ability of NO or inactivation of sGC and not largely from an
increased rate of cGMP degradation via PDE-5. Although
plasma cGMP levels may not completely reﬂect tissue status,
it is nevertheless not surprising that plasma cGMP level did
not rise in the RELAX trial, given that it might be inefﬁcient to
inhibit an enzyme that is not upregulated and likely not
primarily responsible for the cGMP deﬁciency. Further
evidence to this effect was seen in a preclinical study by
Takimoto et al, in which sildenaﬁl produced blunting of
cardiac hypertrophy and ﬁbrosis in mice but failed to increase
cGMP level.30 For a PDE-5 inhibitor to effectively increase
cGMP expression it must rely on sufﬁcient input at the start of
the NO-sGC-cGMP pathway, and the deﬁciency in upstream
pathway activity in HFpEF will likely limit drug efﬁcacy. Indeed,
preclinical studies in erectile dysfunction have shown the
effect of sildenaﬁl to be limited by low NO levels.101
Moreover, and further complicating matters, when PDE-5 is
inhibited, the activity of other phosphodiesterases may
compensate for it.102
Given these experiences with sildenaﬁl, interventions
targeting reductions in NO bioavailability or sGC signaling
are warranted to target the upstream arm of the cGMP
pathway. The recently proposed novel HFpEF paradigm
advocates for the central role of a systemic proinﬂammatory
state favoring coronary microvascular inﬂammation and
reduction in NO, cGMP, and PKG, with consequent increases
in LV hypertrophy and stiffness.25 Among already available
therapies, this paradigm supports the use of statin therapy in
HFpEF given the favorable cholesterol-independent effects on
endothelial dysfunction, NO bioavailability, and LV hypertro-
phy, ﬁbrosis, and diastolic dysfunction, although data on hard
outcomes are limited.103,104 Recent data suggest structured
exercise training may be a practical means of improving peak
oxygen consumption in HFpEF, perhaps through improved
cGMP-mediated peripheral vascular and microcirculatory
function.71,105 Dietary nitrate and nitrate therapy may also
have beneﬁcial cardiovascular effects on endothelial function
and platelet activity.106
Among investigational therapies, agents that target sGC,
including sGC stimulators and activators and neprilysin
inhibitors, represent promising alternatives to increase cGMP
level in HFpEF. All have the advantage of an NO-independent
mechanism that may circumvent problems with inﬂammatory-
mediated NO resistance. In contrast, attenuation of cGMP
catabolism with PDE5 inhibitors may facilitate increases in
oxidative stress and inﬂammation via worsening renal func-
tion, as the high doses of sildenaﬁl used in the RELAX trial
resulted in signiﬁcantly greater increases in creatinine and
cystatin-C.
Clinical trials of drugs in HF have consistently shown
dissociations between acute hemodynamic effects and long-
term outcomes.107,108 In HFpEF, hemodynamic effects
centered on vasodilation should not be a prerequisite for
drug development, due in part to deﬁciencies in stroke volume
reserve. Central hemodynamics in these patients are less
volume dependent and more dependent on peripheral vaso-
tone109,110 Moreover, a subset of HFpEF patients display
hemodynamic derangements primarily during exercise (ie,
high ﬁlling pressures and inadequate cardiac output), whereas
resting hemodynamics remain relatively normal. Applying pure
vasodilator therapies in these patients may improve exercise
hemodynamics at the cost of excessive vasodilation, hypo-
tension, or azotemia in the resting state.59,111 Thus, the ideal
vasoactive agent would offer a modest dilatory effect and
favor concurrent improvement in myocardial performance by
decreasing ventricular stiffness and increasing stroke vol-
ume.110 Accordingly, it will be important for future trials in
cGMP enhancement to dose investigational agents with this
goal in mind.
Unlike acute coronary syndrome, no short-term interven-
tion, with 1 possible exception,112 has been shown to offer
long-term beneﬁt in HF. Similar to HFrEF, future trials in
HFpEF should focus on long-term outcomes and test thera-
pies that are initiated during hospitalization and continued
into the postdischarge period, when patients are at highest
risk of poor outcomes. Likewise, future trials of cGMP
augmentation should preferentially concentrate on develop-
ment of oral therapies that can be used in both the hospital
and outpatient settings. In this regard, focus on the upstream
synthetic pathway for cGMP with use of sGC modulators and
neprilysin inhibitors appears promising. Low-dose oral formu-
lations initiated in stable hospitalized patients and continued
in the ambulatory setting may be ideal to minimize the risk of
hypotension and to explore long-term inﬂuences on mortality
and HFpEF progression that may occur independent of any
vasodilatory action. In addition, enrollment of hospitalized HF
patients identiﬁes a cohort of patients who have a more
certain diagnosis and who are at high risk of subsequent
events, thus improving power to detect a drug effect.
Conclusions
HFpEF is a major public health problem that lacks effective
evidence-based therapies. The cGMP pathway plays a central
role in derangements integral to HFpEF pathophysiology.
Improved characterization of cGMP signaling and its relation
to cardiac function has revealed multiple options for targeted
therapeutic intervention. To date, no large phase III HFpEF
trial has deﬁnitively tested the effects of pharmacologically
mediated increases in cGMP activity. Future prospective
studies are needed to explore the effects of pharmacologi-
cally induced increases in cGMP cell signaling on HFpEF
clinical outcomes.
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